peptidylprolyl isomerase A pseudogene 66Genealiases: []
Q-omics provides the consensus-scored PPIAP66 profile across patient tissues and cancer cell-line models. PPIAP66 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PPIAP66 is differentially expressed in 11, with the highest sampling consensus in BRCA. Additionally, PPIAP66 RNA expression shows 6,660 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BRCA as cancer lineages where PPIAP66 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP66 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP66 survival associations across molecular data types. PPIAP66 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP66 RNA expression–survival associations across cancer types. High PPIAP66 expression shows unfavorable associations in ACC, STAD, LIHC and UVM, but favorable associations in CESC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PPIAP66 RNA expression.
This table summarizes PPIAP66 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP66. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP66 shows lower tumor expression in READ and higher tumor expression in BRCA, LUSC, KIRP, CHOL and HNSC. The BRCA box plot shows higher PPIAP66 RNA expression in tumor versus normal tissue (log2 FC = +0.075, t-test p = .007).
This table shows molecular features associated with PPIAP66 in patient tissues and cancer cell lines. In patient samples, PPIAP66 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
